The Latest Cardiac and Vascular News
CHICAGO, Sept. 21, 2022 /PRNewswire/ — Cardio Diagnostics, Inc. (“Cardio Diagnostics” or the “Company”), a pioneering precision cardiovascular testing company, today announced that the U.S. Patent and Trademark Office has issued to the University of Iowa Research Foundation (“UIRF”) U.S. Patent No. 11,414,704 titled COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE, which is exclusively […]
CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the clearance of its Clinical Trial Authorisation (CTA) application by the United Kingdom (U.K.) Medicines and Healthcare products Regulatory […]
Getinge announces a supply partnership with Medtronic, which recently received CE mark for the Radiant™ covered stent, the first covered stent indicated for chimney endovascular aneurysm repair (ChEVAR). The Radiant covered stent is a private labeled Advanta V12 balloon expandable covered stent produced by Getinge and distributed by Medtronic. The […]
SHANGHAI, Sept. 20, 2022 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, today released the positive results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study on Transcatheter Cardiovascular Therapy conference (TCT 2022),one of the world’s most influential cardiovascular conference. PADN is an innovative radiofrequency ablation technique in treating PH, was recognized as […]
New Data Presented on the Neovasc Reducer™ in Patients With Microvascular Disease VANCOUVER and MINNEAPOLIS, Sept. 20, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced positive clinical data at the Transcatheter Cardiovascular Therapeutics Conference (“TCT”) held September 16-19 in Boston. Prof. Shmuel Banai, MD, Neovasc […]
Statistically significant mean reductions of 10.3 mmHg in 24-hour ambulatory systolic blood pressure and 11.7 mmHg in ambulatory pulse pressure after 6 months of therapy in control patients who crossed over to BackBeat CNT following completion of the randomized portion of the MODERATO II study NEW HOPE, Pa., Sept. 20, […]
Study of the Paradise™ Ultrasound Renal Denervation System Shows significant Reduction in Blood Pressure in Patients with Uncontrolled Hypertension TOKYO–(BUSINESS WIRE)–Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) a wholly owned subsidiary of Otsuka Holdings today announced the detailed results from the RADIANCE II US FDA IDE pivotal trial evaluating […]
BOSTON–(BUSINESS WIRE)–Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis. This study is an update to a 2020 interim analysis and was announced at the 2022 […]
Breakthrough Designation Reinforces Significant Unmet Need in Treatment of Small Vessel Coronary Arteries LOS GATOS, Calif., Sept. 19, 2022 /PRNewswire/ — Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease’s most significant challenges through the creative applications of nanotechnology, today announced the U.S. Food and Drug Administration (FDA) has […]
Results from largest randomized TAVR trial to date presented at TCT 2022 MARLBOROUGH, Mass., Sept. 17, 2022 /PRNewswire/ — Boston Scientific Corporation ( NYSE:BSX) has announced results from the PROTECTED TAVR clinical trial evaluating the SENTINEL™ Cerebral Protection System, which is designed to capture and remove embolic debris stemming from transcatheter aortic valve […]
